RIBOMIC Inc. is engaged in the drug discovery business based on the platform Ribomic Aptamer Refined Therapeutics System related to aptamer drug discovery technology. Its drug discovery business is divided into self discovery and co-discovery divisions. Self Drug Discovery division develops aptamer and licenses and out the results to pharmaceutical companies. The Co-Discovery division earns the research expenses paid by the alliance partner for the shared part of co-discovery business with alliance pharmaceutical companies researching aptamer pharmaceutical.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
21/08/26	JPY 81.00	-2.41%	605,800
20/08/26	JPY 83.00	+6.41%	726,400
19/08/26	JPY 78.00	-3.70%	797,600
18/08/26	JPY 81.00	0.00%	487,800
17/08/26	JPY 81.00	+2.53%	913,900

Delayed Quote Japan Exchange

More quotes

Annual profits - Rate of surprise

Company calendar

Market Closed - Japan Exchange 04:30:00 21/08/26 pm AEST			5-day change	1st Jan Change
81.00 ^JPY	-2.41%		+2.53%	+3.85%

13/08	Ribomic Inc. Reports Earnings Results for the First Quarter Ended June 30, 2026	CI
02/07	Ribomic Enrolls First Patient in Phase III Trials of Umedaptanib Pegol for Achondroplasia Treatment	MT

Market Cap	4.69B 29.56M 25.31M 23.62M 21.67M 40.72M 2.83B 41.52M 280M 109M 1.42B 111M 109M	P/E 2025	-3.89x	P/E 2026	-3.82x
Enterprise Value	1.87B 11.76M 10.07M 9.39M 8.62M 16.19M 1.12B 16.51M 111M 43.43M 564M 44.15M 43.19M	EV / Sales 2025	666x	EV / Sales 2026	651x
Free-Float	97.05%	Yield 2025 *	-	Yield 2026	-

13/08	Ribomic Inc. Reports Earnings Results for the First Quarter Ended June 30, 2026	CI
02/07	Ribomic Enrolls First Patient in Phase III Trials of Umedaptanib Pegol for Achondroplasia Treatment	MT
02/07	Ribomic Inc. Announces First Patient Enrollment In Phase 3 Clinical Trial Of Umedaptanib Pegol For Achondroplasia	CI
14/05	Ribomic Inc. Reports Earnings Results for the Full Year Ended March 31, 2026	CI
19/03	Ribomic Files IND For Phase III Trial Of Achondroplasia Drug In Japan	MT
19/03	Ribomic Inc Announces IND Application for Phase III Clinical Trial of Umedaptanib Pegol for Achondroplasia Treatment	CI
10/03	Ribomic Reports Positive Phase II Results For Achondroplasia Drug	MT
10/03	Ribomic, Inc. Announces Summary Report on Primary Endpoint for Phase Ii Clinical Trial of Umedaptanib Pegol in the Treatment of Achondroplasia	CI
12/02	Ribomic Inc. Reports Earnings Results for the Nine Months Ended December 31, 2025	CI
14/01	Ribomic Files Patent for Anti-Autotaxin Aptamer RBM-006	MT
14/01	RIBOMIC, Inc. Announces New Substance Patent Application for Highly Active RBM-006 (Anti-Autotaxin Aptamer) and its Drug Impact in a Mouse Model of Diabetic Retinopathy	CI
21/11	Ribomic Shows Sustained Two-Year Gains in Achondroplasia Trial	MT
07/10/25	Ribomic Reports Positive Phase 2 Results for Achondroplasia Drug Umedaptanib Pegol	MT

07/10/25	RIBOMIC Announces Positive Phase 2 Cohort 2 Results for Umedaptanib Pegol in Achondroplasia, Demonstrating an Increase in the Annualized Growth Rate of up to +5.0 cm/year with Biweekly Administration in Children Aged 5 Years and Older	BU
05/11/24	RIBOMIC Announces Positive Interim Results from Phase IIa Trial of umedaptanib pegol in Achondroplasia Demonstrating Increase in Annualized Growth Rate of up to +4.6 cm/year in Children 5 Years of Age and Older in the Low Dose Cohort	BU
04/08/24	RIBOMIC Announces Completion of Patient Enrollment in Early Phase II Study of umedaptanib pegol for Achondroplasia and Initiation of Dosing in Cohort 2 of Early Phase II Clinical Study	BU
05/12/23	RIBOMIC Phase I and II Data Published in the Eye: Full TOFU/RAMEN/TEMPURA Trial Results Demonstrate Clinical Proof of Concept of Umedaptanib Pegol in Exudative Age-Related Macular Degeneration (nAMD)	BU
29/07/22	RIBOMIC : Announces Issuance of US Patent for its RBM-010, Novel Drug Candidate for Osteoarthritis	PU

Ribomic Inc. Stock

Stocks

4591

JP3974850004

Biotechnology & Medical Research

Valuation: Ribomic Inc.

Chart: Ribomic Inc.

Latest news : Ribomic Inc.

Press Releases: Ribomic Inc.

News in other languages: Ribomic Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Ribomic Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

08/10/25	RIBOMIC veröffentlicht positive Ergebnisse der Phase-2-Kohorte 2 für Umedaptanib Pegol bei Achondroplasie, die eine Steigerung der annualisierten Wachstumsrate um bis zu +5,0 cm/Jahr bei zweiwöchentlicher Verabreichung bei Kindern ab 5 Jahren zeigen
06/11/24	RIBOMIC gibt positive Zwischenergebnisse der Phase-IIa-Studie mit Umedaptanib Pegol bei Achondroplasie bekannt, die eine Steigerung der annualisierten Wachstumsrate von bis zu +4,6 cm/Jahr bei Kindern ab 5 Jahren in der niedrig dosierten...
20/02/20	RIBOMIC : kündigt erste Injektion in der klinischen Phase-2-Studie von RBM-007 (TOFU-Studie) bei Patienten mit feuchter altersbedingter Makula-Degeneration an
19/06/19	RIBOMIC : gibt positive Topline-Ergebnisse der klinischen Phase-1/2a-Studie an RBM-007 (SUSHI-Studie) bei Patienten mit feuchter altersbedingter Makuladegeneration bekannt

1 day	-2.41%
1 week	+2.53%
Current month	+10.96%
1 month	+8.00%
3 months	+10.96%
6 months	-3.57%
Current year	+3.85%

Manager	Title	Age	Since
Yoshikazu Nakamura PSD	President	78	01/04/2012
Toshiya Imai DFI	Director of Finance/CFO	-	-
Takeo Adachi CTO	Chief Tech/Sci/R&D Officer	39	01/10/2023

Director	Title	Age	Since
Yoshikazu Nakamura BRD	Director/Board Member	78	01/10/2005
Toshiaki Nishihata BRD	Director/Board Member	77	01/06/2016
Takeo Adachi BRD	Director/Board Member	39	01/06/2024

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
RIBOMIC INC.	-2.41%	+2.53%	-21.36%	-44.14%	29.56M
WUXI APPTEC CO., LTD.	+2.38%	+3.43%	+82.88%	+115.89%	73.96B
ARGENX SE	+1.45%	+22.98%	+55.90%	+96.89%	64.66B
INSMED INCORPORATED	+1.31%	+2.13%	-4.69%	+474.45%	27.32B
BIONTECH SE	+7.66%	+26.50%	+6.31%	+0.20%	27.86B
WUXI BIOLOGICS (CAYMAN) INC.	+2.74%	+12.98%	+62.84%	+28.14%	25.97B
GENMAB A/S	+0.89%	+6.61%	+37.29%	-13.39%	19.98B
PHARMAESSENTIA CORPORATION	-1.79%	-4.84%	+239.54%	+414.48%	17.84B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.94%	+3.36%	+18.55%	+532.94%	16.24B
EXELIXIS, INC.	+1.45%	+5.61%	+39.80%	+153.23%	13.3B
Average	+1.48%	+6.49%	+51.71%	+175.87%	28.72B
Weighted average by Cap.	+2.15%	+8.21%	+60.15%	+161.42%

	2025	2026
Net sales	2M 12.6K 10.79K 10.06K 9.23K 17.35K 1.21M 17.69K 119K 46.54K 604K 47.3K 46.27K	3M 18.9K 16.18K 15.1K 13.85K 26.03K 1.81M 26.54K 179K 69.81K 906K 70.95K 69.41K
Net income	-1.02B -6.41M -5.49M -5.12M -4.7M -8.83M -614M -9.01M -60.77M -23.69M -307M -24.08M -23.55M	-1.14B -7.21M -6.18M -5.76M -5.29M -9.93M -690M -10.13M -68.35M -26.64M -346M -27.08M -26.49M
Net Debt	-3.04B -19.13M -16.38M -15.28M -14.02M -26.35M -1.83B -26.87M -181M -70.67M -917M -71.83M -70.27M	-2.83B -17.81M -15.25M -14.23M -13.05M -24.53M -1.7B -25.01M -169M -65.78M -854M -66.86M -65.41M

1 week	77	83
1 month	68	83
Current year	57	120
1 year	57	120
3 years	57	155
5 years	57	944
10 years	57	1,109